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OBJECTIVES The goal of this study was to investigate the relationship between hematocrit (Hct) and left
ventricular mass index (LVMI) and LV hypertrophy (LVH) in subjects without known
hypertension or cardiovascular disease in the Framingham Heart study.
BACKGROUND Anemia may be an independent risk factor for cardiovascular disease in the general
population. One potential explanation for this finding could be an association between Hct
with LVMI or LVH.
METHODS Linear and logistic regression analyses were used to evaluate the association between Hct with
LVMI and LVH. All analyses were stratified by gender and further according to menopausal
status in women.
RESULTS There were 1,376 men and 1,769 women who met the inclusion criteria. The mean Hct and
LVMI were 46.5% and 41.9%, and 127.3 and 95.8 g/m, respectively, in men and women.
After adjustment for confounders, each 3% lower Hct was associated with a 2.6 g/m higher
mean LVMI in men, and a 1.8 g/m higher mean LVMI in postmenopausal women (p 
0.05). There was a significant quadratic relationship between Hct and LVMI in premeno-
pausal women (p  0.01). Subjects in the lowest quartile of Hct (compared with the rest of
the sample) had an adjusted odds ratio of LVH of 2.0 (95% confidence interval [CI] 1.3 to
3.0) in men and 1.4 (95% CI 0.8 to 2.4) in postmenopausal women.
CONCLUSIONS In a sample without known hypertension or cardiovascular disease, a lower Hct is associated
with echocardiographically determined LVH in men and a small but significantly higher
LVMI in men and postmenopausal women. The clinical importance of these findings remains
unknown. (J Am Coll Cardiol 2004;43:1276–82) © 2004 by the American College of
Cardiology Foundationp
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Fnemia is an independent risk factor for adverse cardiovas-
ular outcomes in patients with kidney disease (1), patients
ith left ventricular (LV) dysfunction (2,3), and possibly in
he general population (4). The mechanisms underlying
hese relationships, however, are unknown.
One potential mechanism for the adverse health effects
ssociated with chronic anemia may be an increased cardiac
utput, which may lead to the development of ventricular
ilation, increased LV mass (LVM), and left LV hypertro-
hy (LVH) (5–7). In turn, LVM and LVH are well
stablished predictors of cardiovascular morbidity and mor-
ality (8,9). In fact, there is evidence to suggest that
xperimentally induced anemia causes myocardial hypertro-
hy in a rat model (10). Furthermore, several studies suggest
hat anemia is associated with increased LVM and LVH in
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HRQ T32 HS00060 (Dr. Amin), K23 NIDDK 02904 (Dr. Sarnak), and Amgen
nc., Thousand Oaks, California. The Framingham Heart Study is conducted and
upported by the National Heart, Lung, and Blood Institute (NHLBI) in collabora-
ion with the Framingham Heart Study Investigators. This manuscript was not
repared in collaboration with investigators of the Framingham Heart study and does
ot necessarily reflect the opinions or views of the Framingham Heart Study or
HLBI.
Manuscript received May 13, 2003; revised manuscript received October 17, 2003,accepted October 20, 2003.atients with kidney disease (1,11–14), and treatment of
nemia may result in regression of LVH in patients with
nd-stage renal disease (15–17).
There are limited data, however, that have evaluated the
elationship between level of hematocrit (Hct) with LVM
r LVH in the general population. Previous community-
ased studies examining correlates of LVM have shown that
higher Hct is associated with higher LVM (18–20), but
wo recent reports have also suggested that lower levels of
ct (hemoglobin) are associated with increased LVM as
ell as LV dilation (21,22).
To investigate the relationship between Hct with LVM
nd LVH, we studied subjects without known hypertension
r cardiovascular disease in the Framingham Heart study.
e also examined the association of Hct with LV chamber
ize and wall thickness to better characterize the pattern of
VH.
ETHODS
tudy population and design. The Framingham Heart
tudy is a prospective study established in 1948 to evaluate
otential risk factors for coronary heart disease. The original
ohort consisted of 5,209 male and female residents of
ramingham, Massachusetts, ranging from 28 to 62 years of
ge at study entry. An additional 5,124 individuals (off-
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April 7, 2004:1276–82 Hematocrit and LV Masspring of the original Framingham cohort and their spouses)
ere enrolled into the Framingham Heart study beginning
n 1971. The study design and selection criteria for both
ohorts have been previously described (23–28). The data
or our analyses were obtained from the public use database.
The current retrospective analysis includes participants
ndergoing the 16th biennial examination of the original
ramingham Heart Study and the second biennial exami-
ation of the offspring cohort. Subjects were excluded from
ur analysis if they met any of the following criteria: 1)
chocardiograms of inadequate quality to estimate LV mass;
) history or clinical evidence of coronary heart disease
myocardial infarction, angina pectoris), valvular heart dis-
ase, pulmonary disease, hypertension, diabetes mellitus, or
ongestive heart failure; 3) receiving medications for the
reatment of hypertension; 4) absence of height, weight,
lood pressure, or Hct measurements (29). These exclusion
riteria allowed us to evaluate the relationship between Hct
ith both LVM and LVH with less confounding from
ther variables. Our study sample was, therefore, comprised
f 486 original cohort participants and 2,659 offspring
ohort participants.
ariable measurement. At the time of echocardiographic
xamination, the following variables were measured: Hct,
eight, weight, and blood pressure. Serum creatinine was
ot measured at the time of the 16th examination for
ubjects in the original cohort and, therefore, was not
ncluded in our analyses. Hematocrit was measured using
he Wintrobe method in the original cohort (30) and using
Coulter Counter in the offspring cohort (31). Height and
eight were used to calculate body mass index (in kg per
quare meter). Systolic blood pressure was measured in the
eft arm in the seated position using a mercury column
phygmomanometer. Two physician-measured systolic
lood pressures were averaged to derive the variables used
or analysis (29). Smoking status was defined as either
urrently smoking at the time of visit (offspring cohort) or
urrently smoking at the time of the previous visit (original
ohort). Smoking status was not available at the 16th visit of
he original cohort.
chocardiographic methods. M-mode echocardiograms
ere obtained on original cohort subjects undergoing their
6th biennial examination and offspring cohort subjects
ndergoing their second biennial examination. Two-
Abbreviations and Acronyms
Hct  hematocrit
IVST  interventricular septum thickness
LV  left ventricle/ventricular
LVD  left ventricular diameter
LVDI left ventricular diameter index
LVH  left ventricular hypertrophy
LVMI left ventricular mass index
PWT  left ventricular posterior wall thicknessimensional guided M-mode echocardiograms were per-ormed with subjects in the left lateral decubitus position
rom a parasternal window with a Hoffrel 201 ultrasound
eceiver (Hoffrel Instruments), an Aerotech 2.25-MHz
ransducer (K. B. Aerotech), and a Jason thermographic
rinter (32,33). Echocardiograms were read by Framingham
eart study investigators, and three measurements were
ade and averaged. All measurements were made in accor-
ance with the American Society of Echocardiography
ecommendations (34). End diastolic measurements of LV
iameter (LVD), interventricular septum (IVST), and LV
osterior wall (PWT) were used to calculate LVM (in
rams) from the following formula: LVM 1.05 ([LVD
WT  IVST]3  [LVD]3) (35).
Left ventricular hypertrophy was defined as a LVM
ormalized for height (LV mass index [LVMI]) two SDs or
ore above the mean for a previously defined healthy
eference group within the Framingham Heart study (33).
all thickness was defined as the sum of IVST and PWT,
nd relative wall thickness was calculated as the ratio of wall
hickness to LV diameter at end-diastole. Among the
ubjects who met the above criteria for LVH, eccentric
VH was defined as a relative wall thickness less than 0.45
21).
orrection of LV parameters. It is well appreciated that
eart size differs with body size (36). Previous work from
he Framingham Heart study has shown a significant
ssociation between height and LVM (33). Accordingly,
VM, wall thickness, and end-diastolic internal diameter
ave all been normalized for height.
tatistical methods. Means, SDs, and percentages were
sed to describe baseline demographic and clinical charac-
eristics. Data were stratified by gender (37) and further by
enopausal status for women. We chose to stratify by
enopausal status in women because of well-recognized
hanges in LV structure after menopause (38) and the effect
f menstruation on premenopausal Hct. Tests of differences
etween groups were performed using chi-square tests for
ategorical variables and t tests for continuous variables.
All multivariable regression analysis models evaluating
he association between Hct and LVMI contained variables
hat are known determinants of LVMI. These included age
39), body mass index (29), systolic blood pressure (40), and
moking status (41). Study cohort (original vs. offspring)
as also included into the multivariable model for all
ubgroups. Age, body mass index, and systolic blood pres-
ure were treated as continuous variables. Using ordinary
inear least-squares regression, adjusted increments in
VMI were estimated for decreasing values of Hct. Further
nalyses estimated the adjusted means of LVMI by quartiles
f Hct. A sensitivity analysis was performed to find the
ptimal dichotomous cutoff Hct value and compared to the
owest quartile value for each subgroup. Similar analyses
ere used to assess the relationship between Hct and
nd-diastolic LV diameter, wall thickness, and relative wall
hickness.We fitted restricted cubic splines for Hct in order to
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Hematocrit and LV Mass April 7, 2004:1276–82ssess the functional form of Hct and its relationship with
he various outcomes (42). If the plot indicated a threshold
o transform Hct into a binary variable, we searched for the
ptimal break point that maximized the multivariable mod-
l’s log likelihood. If a significant quadratic relationship
xisted, adjusted parameter estimates or odds ratios (OR)
ere estimated using the middle 50th percentile of the
ample as the reference group.
Logistic regression analysis was used to estimate the
djusted OR (adjusting for the same variables as listed
bove) for LVH by quartiles of Hct. For subjects with LVH
nd low Hct, mean relative wall thickness was calculated to
etermine the pattern of LVH.
We tested for interactions between Hct and study cohort
n men, postmenopausal women, and premenopausal
omen by including a cross-product term in the final model
nd retaining it if significant (p  0.05).
Finally, we performed a sensitivity analysis for all out-
omes after additional adjustment for those subjects who
ad either a systolic blood pressure 140 mm Hg or
iastolic blood pressure 90 mm Hg despite not having a
linical history of hypertension or undergoing treatment for
ypertension.
All statistical tests were two-tailed, and analyses were
erformed using SAS (Cary, North Carolina) version 8.2,
nd nonlinear associations were explored using S-Plus
Insightful Corp., Seattle, Washington) version 6.1.
ESULTS
tudy participants. There were 1,376 men, 760 postmeno-
ausal women, and 1,007 premenopausal women who were
Table 1. Clinical and Echocardiographic Char
Subject Characteristic
Men
(n  1,3
Age (yrs) 45.2 (12
Hematocrit (%) 46.5 (2.
Systolic blood pressure (mm Hg) 123.1 (12
Body mass index (kg/m2) 26.8 (3.
Height (meters) 1.8 (0.
Current smoking status (%) 33.8
Left ventricular mass, ASE (g) 223.2 (47
Left ventricular mass adjusted
for height (g/m)
127.3 (26
End diastolic left ventricular
diameter (mm)
51.0 (3.
Left ventricular wall thickness
(mm)
19.2 (2.
Relative wall thickness 0.38 (0.
Prevalence of LVH (%) 10.2
All data are presented as means (SD) with exception of smo
are presented as percentages.
ASE  American Society of Echocardiography.ncluded in the analysis. The mean Hct and LVMI were6.5%, 42.9%, 41.1%, and 127.3, 101.6, 91.4 g/m in men,
ostmenopausal women, and premenopausal women, re-
pectively. A total of 486 of the subjects were from the
riginal cohort, and 2,659 from the offspring study.
Quartiles of Hct were the following (%): 44.5, 46.4, 48.3
n men, 40.7, 42.9, 44.9 in postmenopausal women, and
9.3, 41.1, 42.9 in premenopausal women. The mean
median) Hct values in the lowest 25th quartile were 42.9
43.3) in men, 39.0 (39.4) in postmenopausal women, and
7.4 (37.9) in premenopausal women. The clinical charac-
eristics of the study population are further summarized in
able 1.
elationship between Hct and LVM. In univariate anal-
sis, Hct was not significantly associated with LVMI in men
p  0.32) or postmenopausal women (p  0.09). After
djusting for previously described confounders, there was a
ignificant, but small, association between Hct and LVMI
n men and postmenopausal women (Table 2, Figs. 1A and
B). Each 3% lower Hct was associated with a 2.55 g/m
igher mean LVMI in men (p  0.001) and 1.80 g/m
igher LVMI in postmenopausal women (p  0.03). There
ere significant (p  0.01) univariate and multivariable
uadratic relationships between Hct and LVMI in pre-
enopausal women (Table 2, Fig. 1C).
Adjusted mean LVMI is shown by quartile of Hct in
igure 2. Mean LVMI was 4.7% higher in men (p 0.001)
nd 1.1% higher in postmenopausal women (p  0.55),
hen the lowest quartile was compared with the rest of the
ample. Mean LVMI was 2.8% higher in premenopausal
omen (p 0.03) when comparing the lowest quartile with
he middle 50th percentile of the sample.
elationship between Hct and LVH. Criteria for LVH
ere met in 140 men (10.2%), 127 postmenopausal women
stics of Study Participants
Postmenopausal
Women
(n  760)
Premenopausal
Women
(n  1,007)
58.7 (9.7) 38.1 (7.1)
42.9 (3.1) 41.1 (2.9)
125.6 (15.7) 112.4 (12.1)
25.9 (4.2) 24.5 (4.2)
1.6 (0.1) 1.6 (0.1)
30.4 35.3
161.2 (39.2) 147.9 (30.7)
101.6 (24.2) 91.4 (18.3)
45.0 (3.7) 46.4 (3.2)
17.6 (2.5) 15.8 (1.7)
0.39 (0.07) 0.34 (0.04)
16.7 5.6
nd prevalence of left ventricular hypertrophy (LVH), whichacteri
76)
.4)
9)
.7)
3)
1)
.6)
.4)
9)
5)
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April 7, 2004:1276–82 Hematocrit and LV Mass16.7%), and 56 premenopausal women (5.6%). The results
f sensitivity analyses identifying optimal Hct cutoff values
or men and postmenopausal women by maximizing the log
ikelihood ratio were similar to the 25th quartile cutoff
alues. Subjects in the lowest quartile of Hct (compared
ith the rest of the sample) had an adjusted OR for LVH
f 2.0 (95% confidence intervals [CI] 1.3 to 3.0) in men, and
.4 (95% CI 0.8 to 2.4) in postmenopausal women. Subjects
n the lowest quartile of Hct (compared with the middle
0% percentile) had an adjusted OR of 1.4 (95% CI 0.6 to
.0) in premenopausal women (Fig. 3).
Among subjects with LVH in the lowest quartile of Hct,
he mean relative wall thickness was 0.42, 0.45, and 0.38 for
en, postmenopausal, and premenopausal women, respec-
ively.
elationship between Hct and LV dimension. Univariate
nalyses showed statistically significant associations between
V diameter indexed for height (LVDI) and Hct in men (p
0.004) and postmenopausal women (p  0.04). In the
ultivariable model, there was a significant (p  0.01), but
mall, association between LVDI and Hct in men and
ostmenopausal women (Table 2). There were significant
nivariate (p  0.01) and multivariable (p  0.005) qua-
ratic relationships between Hct and LVDI in premeno-
ausal women.
Comparing the lowest quartile with the rest of the
ample, mean LVDI was 1.5% higher in men (p  0.001),
able 2. Relationship of Hematocrit to LVM, End-Diastolic
imension, and Wall Thickness
Men
LVM/ht LVD/ht SWT/ht RWT
CT 0.72 0.18* 0.06 0.01*
CTA 2.55* 0.26* 0.03 0.002
CT25% 5.88* 0.43* 0.19* 0.0006
Postmenopausal Women
LVM/ht LVD/ht SWT/ht RWT
CT 1.43 0.17* 0.21* 0.01*
CTA 1.80* 0.25* 0.07 0.001
CT25% 1.10 0.37 0.06 0.003
Premenopausal Women
LVM/ht LVD/ht SWT/ht RWT
CT25%U 2.57* 0.17 0.13 0.002
ll values are parameter estimates, which refer to the coefficient for the hematocrit
ariable in the linear regression model. *p value 0.05.
HCT  parameter estimates for a decrease in hematocrit of 3% in univariate
nalysis; HCTA  parameter estimates for a decrease in hematocrit of 3% in
ultivariable analysis after controlling for age, systolic blood pressure, body-mass
ndex, smoking status, and study cohort (original vs. offspring); HCT25%  fully
djusted parameter estimates comparing lowest quartile to rest of sample population;
CT25%U  fully adjusted parameter estimates comparing lowest quartile to middle
0% percentile; LVD/ht  end-diastolic left ventricular diameter indexed for height;
VM/ht  left ventricular mass indexed for height; RWT  relative wall thickness;
WT/ht  the sum of posterior wall and interventricular wall thickness at end-
iastole indexed for height.nd 1.3% higher in postmenopausal women (p  0.06) HTable 2). Mean LVDI was 0.6% higher in premenopausal
omen (p  0.23) when comparing the lowest quartile of
igure 1. (A) Relationship between hematocrit and left ventricular mass
LVM) index in men. (B) Relationship between hematocrit and LVM
ndex in postmenopausal women. (C) Relationship between hematocrit
nd LVM index in premenopausal women. Hematocrit is treated as a
ontinuous variable; LVM index is LVM normalized for height (g/m). All
elationships shown are fully adjusted restricted cubic spline estimates for
he relationship between hematocrit and LVM index. Other covariates in
he multivariable model include: age, systolic blood pressure, body mass
ndex, smoking status, and study cohort (original vs. offspring). Dashed
ines  95% confidence intervals.ct with the middle 50th percentile of the sample.
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Hematocrit and LV Mass April 7, 2004:1276–82elationship between Hct and relative wall thickness.
fter adjusting for confounders, there was no association
etween Hct and relative wall thickness in men, postmeno-
ausal women, or premenopausal women (Table 2).
nteractions and sensitivity analysis. There were no sig-
ificant interactions between Hct and study cohort with
VMI, LVDI, or LVH as outcomes in any of the
ubgroups.
In a sensitivity analysis after additional adjustment for
ubjects with a systolic blood pressure 140 mm Hg or
igure 2. All values shown are fully adjusted mean left ventricular mass
LVM) indices. Covariates in multivariable model include: age, systolic
lood pressure, body mass index, smoking status, and study cohort (original
s. offspring). Left ventricular mass index is LVM normalized for height
g/m). Hematocrit quartiles are the following (%): 44.5, 46.5, 48.3 in men,
0.8, 43.0, 45.0 in postmenopausal women, and 39.3, 41.1, 43.0 in
remenopausal women. Mean (median) hematocrit values by quartile are
he following (%): 42.9 (43.3), 45.5 (45.6), 47.3 (47.3), 50.2 (49.9) in men,
9.0 (39.4), 41.9 (42.0), 43.7 (43.7), 46.6 (46.0) in postmenopausal
omen, and 37.4 (37.9), 40.3 (40.3), 42.1 (42.0), 44.6 (44.4) in premeno-
ausal women. Open bars men; closed bars postmenopausal women;
triped bars  premenopausal women.
igure 3. Values shown are fully adjusted odds ratios (OR) with corre-
ponding 95% confidence intervals comparing lowest quartile to rest of
tudy sample in men and postmenopausal women, and to middle 50% of
tudy sample in premenopausal women. Covariates in multivariable model
nclude age, systolic blood pressure, body mass index, smoking status, andttudy cohort (original vs. offspring). LVH  left ventricular hypertrophy.iastolic blood pressure 90 mm Hg, the results did not
ignificantly change (data not shown).
ISCUSSION
hronic severe anemia is known to result in increased
ardiac output that may lead to the development of LVH
5). The latter has been well appreciated in patients who are
nemic secondary to kidney disease (11,43) and sickle cell
isease (44). To the best of our knowledge, however, this
ssociation has not been demonstrated at less severe degrees
f anemia in the general population. The results of our study
uggest that, in subjects without known hypertension or
ardiovascular disease, lower levels of Hct are associated
ith a small increase in LVMI in men and postmenopausal
omen, and increased LVH in men.
Previous studies evaluating the relationship between
hronic anemia and adaptive changes in cardiac geometry
ave primarily focused on patients with kidney disease or
ther extreme forms of anemia. In fact, there are limited
ublished data regarding this topic in the general popula-
ion. Astor and colleagues (22) recently evaluated middle-
ged African American participants of the Atherosclerosis
isk in Communities study and noted that lower levels of
emoglobin are associated with elevated LVMI and LV
ilation (22). This analysis, however, included subjects with
otentially confounding pre-existing conditions (e.g., hy-
ertension and cardiovascular disease) and used hemoglobin
alues taken an average of three to six years before the time
f echocardiogram. Our study evaluated subjects free of
reexisting cardiovascular comorbidity who had Hct values
aken at the time of echocardiography, and, therefore,
llows for a more direct evaluation of the relationship
etween Hct and LVMI. In a smaller retrospective analysis,
chunkert and colleagues (21) demonstrated an association
etween lower Hct levels and LV dilation, suggesting a
attern of eccentric LVH at the lowest Hct extreme. The
esults of our study are consistent with these findings, and
upport the notion that chronically low levels of Hct may
ontribute to LV remodeling and potentially to the devel-
pment of LVH in the general population.
Our study demonstrates a significant, albeit small, asso-
iation between lower levels of Hct and higher LVMI in
oth men and postmenopausal women, a U shaped rela-
ionship between Hct and LVMI in premenopausal women,
nd an association between low levels of Hct and LVH in
en. Although some of these differences may be due to
ower limitations, differences in cardiac remodeling be-
ween pre- and postmenopausal women and between men
nd women may be playing a role (38,45–47).
Given that LVH in the general population predicts
ardiovascular morbidity and mortality (8), the association
e have demonstrated between lower levels of Hct and
VH in men may be important. Furthermore, values in the
owest quartile of Hct were not as low as values previously
hought to induce cardiac remodeling. For example, the
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April 7, 2004:1276–82 Hematocrit and LV Massean (median) Hct value in the lowest quartile in men was
2.9% (43.3%). This association raises the question as to
hether a chronic Hct in the low-normal range may result
n alterations in LV morphology.
Classically, anemia has been associated with eccentric LV
rowth, which is characterized by a proportionate increase
n LV diameter and wall thickness. Most of the published
ata in support of this association has been derived in
atients with kidney disease and patients with extreme
orms of anemia (48–51). Our results suggest that the
attern of LVH associated with low Hct involves both an
ncrease in wall thickness and an increase in LV cavity size.
hat is, the mean relative wall thickness did not change
cross levels of Hct supporting an association with eccentric
VH (Table 2). Furthermore, the mean relative wall thick-
ess of those with LVH and low Hct remains less than or
qual to 0.45 in all subgroups, which, by definition, is
onsistent with eccentric LVH (21). Thus, our findings are
onsistent with known physiologic processes in specific
ubpopulations and suggest a similar relation in otherwise
ealthy subjects.
tudy limitations. There are potential limitations to the
resent study results. First, given the observational nature of
ur study, it is possible that the association between Hct and
chocardiographic parameters of LVM is due to unrecog-
ized confounding factors that affect both Hct and LVMI.
e have attempted to address this limitation by excluding
ndividuals with a history of diabetes, cardiovascular disease,
r pulmonary disease. The observational design of the study,
owever, precludes our ability to ascribe cause and effect
elationships. Second, our analysis only takes into account
easurement of Hct at one point in time and, thus,
uration of anemia is unknown. This may be less of a
onsideration for relatively healthy men and postmeno-
ausal women who presumably have more stable blood
ounts. Hematocrit measurements in premenopausal
omen, however, inherently fluctuate more and are, thus,
ess reliable. In this respect, we note that the association
etween Hct and LVMI was different in the premenopausal
ubgroup.
Third, Hct was measured using different methods in the
wo Framingham Heart study cohorts. For each outcome,
owever, there was no significant interaction between Hct
nd cohort in men, postmenopausal women, or premeno-
ausal women. Furthermore, we found similar parameter
stimates for all continuous outcomes and similar adjusted
Rs for LVH in all subgroups when stratifying by cohort
data not shown). Thus, we believe the difference in the
ethod of Hct measurement between Framingham Heart
tudy cohorts is less concerning. Moreover, any artificial
ariability in Hct values due to laboratory measurement
ould likely reduce, rather than enhance, the observed
elationships between Hct and LVM.
Finally, the generalizability of our results is also limited in
hat all of the participants were Caucasian. Recent data from
stor et al. (22), however, describe a similar associationetween hemoglobin and LVMI in African American
articipants of the Atherosclerosis Risk in Communities
tudy (22), suggesting a consistency of this relationship
mong different races.
onclusions. The results of this study suggest that, in a
arge well-characterized sample without known hyperten-
ion or cardiovascular disease, a lower Hct is associated with
chocardiographically determined LVH in men and a small,
ut significantly higher, LVMI in men and postmenopausal
omen. The clinical importance of these findings remains
nknown. Future studies are required to confirm this
nding and to evaluate whether the relationship between
ct and LV mass is due to a cause and effect relationship.
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